Rxo (RXO) Total Liabilities (2021 - 2026)

Rxo (RXO) has reported Total Liabilities for 6 consecutive years, with $2.0 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Total Liabilities rose 21.08% year-over-year to $2.0 billion; the trailing twelve-month figure through Jun 2026 stood at $2.0 billion (up 21.08% YoY), and the FY2025 full-year result was $1.7 billion, down 3.66% from the prior year.
• Total Liabilities improved to $2.0 billion in Q2 2026 per RXO's latest filing, from $1.8 billion in the prior quarter.
• Across five years, Total Liabilities topped out at $2.0 billion in Q2 2026 and bottomed at -$1.2 billion in Q2 2022.
• Historically, Total Liabilities has averaged $1.2 billion across 5 years, with a median of $1.4 billion in 2022.
• The sharpest annual moves came in 2023 and 2024: Total Liabilities soared 237.39% in 2023, then dropped 15.07% in 2024.
• Over 5 years, Total Liabilities stood at $1.4 billion in 2022, then decreased by 14.75% to $1.2 billion in 2023, then surged by 46.39% to $1.8 billion in 2024, then decreased by 3.66% to $1.7 billion in 2025, then gained by 12.5% to $2.0 billion in 2026.
• According to Business Quant data, Total Liabilities over the past three periods registered $2.0 billion, $1.8 billion, and $1.7 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.